HCPLive Network

'Doctor Shoppers' Account for Less Than 2 Percent of All Opioid Prescriptions

THURSDAY, July 18 (HealthDay News) -- A small proportion of opioid prescription purchasers (0.7 percent) obtain an average of 32 prescriptions from 10 different prescribers, accounting for 1.9 percent of all opioid prescriptions, according to a study published online July 17 in PLOS ONE.

Douglas C. McDonald, PhD, and Kenneth E. Carlson, from Abt Associates Inc. in Cambridge, MA, examined the prevalence of doctor shopping to obtain multiple opioid prescriptions and the amounts and types of opioids involved. Records were reviewed for 146.1 million opioid prescriptions dispensed by 76 percent of U.S. retail pharmacies during 2008. Prescriptions were linked to unique patients.

The researchers found that patients in the extreme outlying population (0.7 percent of purchasers), who were thought to be doctor shoppers, obtained 32 prescriptions for opioids from 10 different prescribers, on average. This group purchased 1.9 percent of all opioid prescriptions, constituting 4 percent of the total weighed amounts that were dispensed.

"To close the information gap that makes doctor shopping and uncoordinated care possible, states have created prescription drug monitoring programs to collect records of scheduled drugs dispensed, but the majority of physicians do not access this information," the authors write. "To facilitate use by busy practitioners, most monitoring programs should improve access and response time, scan prescription data to flag suspicious purchasing patterns, and alert physicians and pharmacists."

The authors are employees of Abt Associates Inc., a commercial scientific research company.

Full Text

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
For patients with type 1 diabetes, long-term weighted mean hemoglobin A1c is associated with development of severe microvascular complications, according to a study published online Dec. 15 in Diabetes Care.
Rapivab (peramivir injection) is an intravenous neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza in patients 18 years and older.
Lynparza (olaparib) has been approved by the US Food and Drug Administration to treat advanced ovarian cancer associated with defective BRCA genes, the agency said Friday in a news release.
More Reading